Denali Therapeutics Inc. (DNLI)
NASDAQ · Healthcare
Denali Therapeutics Inc. Operating Income 2016–2025
Denali Therapeutics Inc. annual/quarterly operating income history and growth rate from 2016 to 2024. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Denali Therapeutics Inc. operating income for the quarter ending September 30, 2024 was -123.2 M, a 8.25% increase year-over-year.
- Denali Therapeutics Inc. operating income for the twelve months ending September 30, 2024 was -471.3 M, a 295.26% increase year-over-year.
- Denali Therapeutics Inc. annual operating income for 2025 was -555.3 M, a 13.95% increase from 2024.
- Denali Therapeutics Inc. annual operating income for 2024 was -487.3 M, a 147.76% increase from 2023.
- Denali Therapeutics Inc. annual operating income for 2023 was -196.7 M, a 42.27% decrease from 2022.
- Denali Therapeutics Inc. annual operating income for 2022 was -340.7 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Denali Therapeutics Inc. Operating Income — FAQ
Denali Therapeutics Inc. (DNLI) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Denali Therapeutics Inc.'s operating income?
Denali Therapeutics Inc. (DNLI) reported operating income of -$555M for fiscal 2025.
Where can I see DNLI's operating income history?
The chart and table above show Denali Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.